Patents Examined by Carlos Azpura
  • Patent number: 6056950
    Abstract: The polysaccharide fraction of tamarind gum, a product of natural origin obtained from the seeds of Tamarindus indica, is used for the production of a thickened ophthalmic solution having a pseudoplastic rheological behaviour and mucoadhesive properties. Said solution is useful as artificial tear and as vehicle for sustained release ophthalmic drugs. The concentrations of tamarind seed polysaccharide preferably employed in ophthalmic preparations for use as artificial tears, i.e. as products for replacing and stabilising the natural tear fluid, particularly indicated for the treatment of dry eye syndrome, are comprised between 0.7 and 1.5% by weight. The concentrations of tamarind seed polysaccharide preferably employed in the production of vehicles (i.e. delivery systems) for ophthalmic drugs, having the function of prolonging the permanence time of said medicaments at their site of action, are comprised between 1 and 4% by weight.
    Type: Grant
    Filed: August 5, 1998
    Date of Patent: May 2, 2000
    Assignee: Farmigea S.p.A.
    Inventors: Marco Fabrizio Saettone, Susi Burgalassi, Boris Giannaccini, Enrico Boldrini, Pietro Bianchini, Giulio Luciani
  • Patent number: 5108754
    Abstract: A method for preventing the sickling of sickle cells in a patient having sickle cell disease, the method which comprises administering to the patient a therapeutically effective amount of a compound having the formula: ##STR1## wherein X.sup.- is selected from the group consisting of iodide, chloride, bromide, hydroxyl, nitrite, phosphate and acetate.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: April 28, 1992
    Inventor: Michael Wilburn
  • Patent number: 5077284
    Abstract: The steroid hormone dehydroepiandrosterone (DHEA), when administered by feeding or by subcutaneous injection, significantly improves the host response to viral infection. Experimental animal data shows that, with infection (100,000 plaque forming units/animal) of a human coxsackievirus B4 strain, which causes mortality in about 90% of infected animals, mortality was reduced to 37% when animals were treated with DHEA. Moreover, DHEA induced an 80% elevation in the number of antibody forming cells, particularly in cells forming gamma globulin M (early antibodies), and gamma globulin G (secondary antibodies). This elevation in the number of antibody forming cells was evident only in DHEA treated and virus infected animals, but not in uninfected animals treated with DHEA or in infected animals not treated with DHEA. In virus infected and DHEA treated animals there was also an elevation in the number of monocyte cells, the particular white blood cell associated with a resistance to this infection.
    Type: Grant
    Filed: December 30, 1988
    Date of Patent: December 31, 1991
    Inventors: Roger M. Loria, William Regelson
  • Patent number: 5075287
    Abstract: Muramyl peptide derivatives of the formula: ##STR1## wherein "Ala" is ##STR2## "isoGln" is ##STR3## R.sup.1 is R.sub.3 O-- or ##STR4## (k is an integer from 8 to 12; q is an integer from 10 to 22) or R.sub.3 is ##STR5## (m is an integer from 11 to 17; n is an integer from 11 to 17)]; and R.sub.2 is hydrogen atom or --CO--(CH.sub.2).sub.p --CH.sub.3 (p is an integer from 8 to 22); which act on in vivo immunomechanism of human beings and livestock (in particular cells relevant immune responses) and are useful as imminoregulating agents.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: December 24, 1991
    Assignee: Nisshin Oil Mills, Inc.
    Inventor: Akira Hasegawa
  • Patent number: 4990529
    Abstract: 2-Pyrazoline derivatives of the formula (A): ##STR1## where R.sup.1 is a pyridyl, a pyrazyl or an alkoxyl group; and R.sup.2 is a hydrogen atom, an alkyl, a pyridyl, a furyl, phenyl or a substituted phenyl group, and to a process for producing the same. Therapeutic agents for treating cerebrovascular diseases containing, as the active ingredient, a 2-pyrazoline derivative represented by the formula (G): ##STR2## where R.sup.3 is a hydrogen atom, an alkyl, acetyl, an alkoxycarbonyl, an amino, benzoyl, a substituted benzoyl, a pyridylcarbonyl, a furylcabonyl, a thienylcarbonyl, a pyrazylocarbonyl, an N-substituted carbamoyl, an N-substituted thiocarbamoyl, or carboxyl group; and R.sup.4 is a hydrogen atom, an alkyl, a pyridyl, a thienyl, a furyl, cyclohexyl, phenyl or a substituted phenyl group or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 6, 1989
    Date of Patent: February 5, 1991
    Assignee: Mitsui Toatsu Chemicals
    Inventors: Hiroyuki Yamashita, Makoto Odate, Hajime Iizuka, Hiroshi Kawazura, Yoshio Shiga, Hiroshi Namekawa
  • Patent number: 4950664
    Abstract: Nasal administration of benzodiazepines is described as providing improved therapeutic effects as compared to conventional delivery techniques. The compositions comprise a benzodiazepine hypnotic in a pharmaceutically acceptable nasal carrier.
    Type: Grant
    Filed: September 16, 1988
    Date of Patent: August 21, 1990
    Assignee: Rugby-Darby Group Companies, Inc.
    Inventor: Arthur H. Goldberg